News & Updates
Filter by Specialty:
FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma
An open-label single-arm phase II trial of FOLFOX and nab-paclitaxel (FOLFOX-A) reports a target-exceeding objective response rate (ORR) and a more favourable haematologic toxicity profile than triplet regimen historical controls in metastatic/advanced unresectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
FOLFOX plus nab-paclitaxel exceeds expected ORR, shows favourable haematotoxicity in gastric/GEJ adenocarcinoma
20 Dec 2024
CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
The 5-year update of the phase III CameL study of camrelizumab plus carboplatin and pemetrexed (C+CP) in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations demonstrates continued overall survival (OS) and progression-free survival (PFS) benefits.
CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
19 Dec 2024
Pembrolizumab extends survival in advanced melanoma
Patients with advanced melanoma achieve long-term survival with the use of pembrolizumab, as shown by the results of the 10-year follow-up of the phase III KEYNOTE-006 study.
Pembrolizumab extends survival in advanced melanoma
18 Dec 2024
Salbutamol may lower risk, improve prognosis of prostate cancer
The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.
Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024
Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.